-
EP4159238
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4159238
| EP4159238 - COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 03.03.2023 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 10.12.2021 | Most recent event Tooltip | 05.07.2024 | Supplementary search report | published on 07.08.2024 [2024/32] | 05.07.2024 | Change - classification | published on 07.08.2024 [2024/32] | 05.07.2024 | Change - classification | published on 07.08.2024 [2024/32] | Applicant(s) | For all designated states CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. No. 369 Yuzhou South Rd. Lianyungang Jiangsu 222062 / CN | For all designated states Tianjin Medical University Cancer Institute and Hospital Huanhuxi Road Tiyuanbei Hexi District Tianjin 300060 / CN | [2023/14] | Inventor(s) | 01 /
ZHANG, Xiquan Lianyungang, Jiangsu 222062 / CN | 02 /
WANG, Xunqiang Lianyungang, Jiangsu 222062 / CN | 03 /
YU, Ding Lianyungang, Jiangsu 222062 / CN | 04 /
LIU, Tao Lianyungang, Jiangsu 222062 / CN | 05 /
ZHAN, Xiaole Lianyungang, Jiangsu 222062 / CN | 06 /
WU, Naiying Lianyungang, Jiangsu 222062 / CN | [2023/14] | Representative(s) | Kraus & Lederer PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE | [N/P] |
| Former [2023/14] | Ladendorf, Oliver Kraus & Weisert Patentanwälte PartGmbB Thomas-Wimmer-Ring 15 80539 München / DE | Application number, filing date | 21817364.9 | 01.06.2021 | [2023/14] | WO2021CN97776 | Priority number, date | CN202010489252 | 02.06.2020 Original published format: CN202010489252 | CN202010489236 | 02.06.2020 Original published format: CN202010489236 | [2023/14] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021244551 | Date: | 09.12.2021 | Language: | ZH | [2021/49] | Type: | A1 Application with search report | No.: | EP4159238 | Date: | 05.04.2023 | Language: | EN | [2023/14] | Search report(s) | International search report - published on: | CN | 09.12.2021 | (Supplementary) European search report - dispatched on: | EP | 04.07.2024 | Classification | IPC: | C07K16/28, A61K39/395, C07D215/22, A61P35/00, A61K31/00 | [2024/32] | CPC: |
A61P35/00 (EP,US);
A61K31/47 (EP,US);
A61K39/395 (EP);
A61K39/3955 (US);
C07D215/22 (EP);
C07K16/2827 (EP);
A61K2039/505 (EP);
A61K2039/545 (US);
C07K2317/24 (EP);
C07K2317/76 (EP)
(-)
| C-Set: |
A61K31/47, A61K2300/00 (EP);
A61K39/395, A61K2300/00 (EP) |
| Former IPC [2023/14] | A61K39/395, C07D215/22, C07K16/28, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/14] | Title | German: | KOMBINIERTE PHARMAZEUTISCHE ZUSAMMENSETZUNG AUS C-MET-KINASEHEMMER UND ANTI-PD-L1-ANTIKÖRPER | [2023/14] | English: | COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY | [2023/14] | French: | COMPOSITION PHARMACEUTIQUE COMBINÉE D'INHIBITEUR DE KINASE C-MET ET D'ANTICORPS ANTI-PD-L1 | [2023/14] | Entry into regional phase | 29.12.2022 | Translation filed | 29.12.2022 | National basic fee paid | 29.12.2022 | Search fee paid | 29.12.2022 | Designation fee(s) paid | 29.12.2022 | Examination fee paid | Examination procedure | 29.12.2022 | Amendment by applicant (claims and/or description) | 29.12.2022 | Examination requested [2023/14] | Fees paid | Renewal fee | 31.03.2023 | Renewal fee patent year 03 | 04.06.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2012034055 (ADVENCHEN LAB LLC [US]); | [A]US8420645 (WENG LINGKAI [US], et al); | [Y]WO2016022630 (ZHA JIPING [CN], et al); | [Y]WO2016061142 (NOVARTIS AG [CH], et al); | [Y]US2019224200 (MARTIN ERIC SANTOS [US], et al); | International search | [Y]CN103328447 (ADVENCHEN LAB LLC, et al); | [Y]WO2016040892 (NOVARTIS AG [CH], et al); | [Y]JP2016155776 (HYOGO COLLEGE MEDICINE); | [Y]CN107001463 (ZHA JIPING, et al); | [A]WO2019085982 (NANJING SHUNXIN PHARMACEUTICAL CO LTD [CN], et al); | [Y]WO2019161320 (APOLLOMICS INC [GB], et al); | [A]WO2020015703 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD [CN]); | by applicant | WO2012034055 | WO2016022630 | CN107001463 |